Respiratory Syncytial Virus Vaccines: A Review of the Candidates and the Approved Vaccines
Pathogens · 19.10.2023 · 12 (10) · 1259
DOI: 10.3390/pathogens12101259 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pathogens, online erschienen am 19.10.2023. Verfasst von Xanthippi Topalidou und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology, School of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece. Die Arbeit wurde bisher 126-mal zitiert (Crossref) und nennt 151 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Respiratory syncytial virus (RSV) is responsible for a significant proportion of global morbidity and mortality affecting young children and older adults. In the aftermath of formalin-inactivated RSV vaccine development, the effort to develop an immunizing agent was carefully guided by epidemiologic and pathophysiological evidence of the virus, including various vaccine technologies. The pipeline of RSV vaccine development includes messenger ribonucleic acid (mRNA), live-attenuated (LAV), subunit, and recombinant vector-based vaccine candidates targeting different virus proteins. The availability of vaccine candidates of various technologies enables adjustment to the individualized needs of each vulnerable age group. Arexvy® (GSK), followed by Abrysvo® (Pfizer), is the first vaccine available for market use as an immunizing agent to prevent lower respiratory tract disease in older adults. Abrysvo is additionally indicated for the passive immunization of infants by maternal administration during pregnancy. This review presents the RSV vaccine pipeline, analyzing the results of clinical trials. The key features of each vaccine technology are also mentioned. Currently, 24 vaccines are in the clinical stage of development, including the 2 licensed vaccines. Research in the field of RSV vaccination, including the pharmacovigilance methods of already approved vaccines, promotes the achievement of successful prevention.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Pharmacology, School of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
- Millennium Institute of Immunology and Immunotherapy, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago 8320000, Chile.
- Departamento de Endocrinología, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago 8320000, Chile.
- Clinical Research Unit, Special Unit for Biomedical Research and Education, School of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
ORCID-Profile: Xanthippi Topalidou, Alexis M Kalergis, Georgios Papazisis
Zitieren
APA
Topalidou, X., Kalergis, A. M., & Papazisis, G. (2023). Respiratory Syncytial Virus Vaccines: A Review of the Candidates and the Approved Vaccines. Pathogens, 12(10), 1259. https://doi.org/10.3390/pathogens12101259
Vancouver
Topalidou X, Kalergis AM, Papazisis G. Respiratory Syncytial Virus Vaccines: A Review of the Candidates and the Approved Vaccines. Pathogens. 2023;12(10):1259. doi:10.3390/pathogens12101259
BibTeX
@article{Topalidou2023,
author = {Topalidou, Xanthippi and Kalergis, Alexis M and Papazisis, Georgios},
title = {Respiratory Syncytial Virus Vaccines: A Review of the Candidates and the Approved Vaccines},
journal = {Pathogens},
year = {2023},
volume = {12},
number = {10},
pages = {1259},
doi = {10.3390/pathogens12101259}
}
EUVIMED